Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Lumos Pharma stock | $23.4

Own Lumos Pharma stock in just a few minutes.

Fact checked

Lumos Pharma, Inc is a biotechnology business based in the US. Lumos Pharma shares (LUMO) are listed on the NASDAQ and all prices are listed in US Dollars. Lumos Pharma employs 28 staff and has a market cap (total outstanding shares value) of USD$238.8 million.

How to buy shares in Lumos Pharma

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Lumos Pharma. Find the stock by name or ticker symbol: LUMO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Lumos Pharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$23.4, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Lumos Pharma, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Lumos Pharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Lumos Pharma share price

Use our graph to track the performance of LUMO stocks over time.

Lumos Pharma shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$23.4
52-week rangeUSD$6.7436 - USD$31.87
50-day moving average USD$17.7567
200-day moving average USD$15.5512
Wall St. target priceUSD$33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-10.3742

Buy Lumos Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Forex
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Bonds
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Lumos Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lumos Pharma price performance over time

Historical closes compared with the close of $23.4 from 2020-12-18

1 week (2021-01-12) 5.41%
1 month (2020-12-22) -6.40%
3 months (2020-10-20) 71.68%
6 months (2020-07-20) 46.25%
1 year (2020-01-18) N/A
2 years (2019-01-18) 1,439.47%
3 years (2018-01-19) 171.46%
5 years (2016-01-20) 28.2

Lumos Pharma financials

Gross profit TTM USD$0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation USD$238.8 million

TTM: trailing 12 months

Shorting Lumos Pharma shares

There are currently 169,480 Lumos Pharma shares held short by investors – that's known as Lumos Pharma's "short interest". This figure is 6.8% down from 181,809 last month.

There are a few different ways that this level of interest in shorting Lumos Pharma shares can be evaluated.

Lumos Pharma's "short interest ratio" (SIR)

Lumos Pharma's "short interest ratio" (SIR) is the quantity of Lumos Pharma shares currently shorted divided by the average quantity of Lumos Pharma shares traded daily (recently around 12210.374639769). Lumos Pharma's SIR currently stands at 13.88. In other words for every 100,000 Lumos Pharma shares traded daily on the market, roughly 13880 shares are currently held short.

However Lumos Pharma's short interest can also be evaluated against the total number of Lumos Pharma shares, or, against the total number of tradable Lumos Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lumos Pharma's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Lumos Pharma shares in existence, roughly 20 shares are currently held short) or 0.0356% of the tradable shares (for every 100,000 tradable Lumos Pharma shares, roughly 36 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Lumos Pharma.

Find out more about how you can short Lumos Pharma stock.

Lumos Pharma share dividends

We're not expecting Lumos Pharma to pay a dividend over the next 12 months.

Have Lumos Pharma's shares ever split?

Lumos Pharma's shares were split on a 1:9 basis on 19 March 2020. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lumos Pharma shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Lumos Pharma shares which in turn could have impacted Lumos Pharma's share price.

Lumos Pharma overview

Lumos Pharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for severe, rare, and genetic diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency. The company has a licensing agreement with Ellipses Pharma Limited for the development of and rights to commercialize nanoparticle formulations of two therapeutics for oncology indications. Lumos Pharma, Inc. was founded in 2011 and is headquartered in Austin, Texas.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site